OWC Pharmaceutical Research to Present at Lyons Capital’s Wall Street Conference

PETACH TIKVA, Israel, February 17, 2017 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it will be presenting at the Wall Street Conference. The event will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach/ Boca Raton, Florida, on Wednesday, March 1, 2017.

     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )

The Wall Street Conference is the premiere conference in the venture capital arena and small-cap marketplace. Conference participants include industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, who attend to discuss significant trends in the financial markets. 

Ziv Turner, OWCP's VP Business development and Managing Director of One World Cannabis, the Company's wholly-owned subsidiary, will provide conference attendees with an update about the Company's progress, specifically focused on its research and products in development, and most importantly the Company's plans for the future, sales and marketing in the US, Canada and Europe this year (2017). The Company is currently scheduled to give its presentation on or around 3:30 PM, as a follow to its advisory board member, Mr. Jeffery Friedland's key tone session. Other management team members, Mr. Mordehai Bignitz, Chairman and CEO and Dr. Yehuda Baruch, Chief Science Officer will also be available for one-on-one discussions during the conference.

Mr. Turner commented on the Company's participation in the event, "The Wall Street Conference is one of the leading conferences for small-cap investors and OWC is excited to be a part of it. OWC continues to make significant progress in the research and development of cannabis-centric medical treatments, specifically with our psoriasis cream, which is being readied for the U.S. and European markets.  We are focused on having our products on the shelves in the MMJ states this year. I am very much looking forward to discussing the Company with conference attendees."

Jeffrey Friedland, a leader in the cannabis sector, author of Marijuana: The World's Most Misunderstood Plant, and a member of the Company's Advisory Board, is a featured speaker at the Conference. He is expected to discuss the opportunities for public company investments in the cannabis sector, and the positive impact that Israeli science and companies are having on the U.S. and Canadian cannabis markets. Mr. Friedland is CEO of Intiva Inc., which was an early-stage investor in OWC, and which made its investment in the Company during the summer of 2014.

When asked about his participation at the conference, Mr. Friedland stated, "The legal cannabis market has expanded considerably over the past two years, generating significant and growing investor interest. However, there are only a handful of publicly-traded companies focused on cannabinoid-based, pharmaceutical development and a true scientific approach to product development. I intend to discuss what I see as the publicly-traded cannabis opportunities at the Conference."

Subject to his schedule, Mr. Friedland will also be available for private meetings during the conference.

About OWC Pharmaceutical Research Corp.    

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com

Notice Regarding Forward-Looking Statements   

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information:

In Israel:
Ziv Turner, VP Business development and managing director of - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659

SOURCE OWC Pharmaceutical Research Corp.